Article Sidebar
Published:
Apr 14, 2024DOI:
10.4314/tjpr.v23i3.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Bergamot regulates oxidized low density lipoprotein induced inflammation and foam cell formation of human umbilical vein endothelial cells by regulating SIRT1/NF κB pathway
Abstract
Purpose: To investigate the effects of bergamot (BGM) on the progression of atherosclerosis, and to unravel the mechanism of action.
Methods: Oxidized low-density lipoprotein (Ox-LDL)-induced HUVECs were used as an in vitro model of atherosclerosis. CCK-8, flow cytometry (FCM), and enzyme-linked Immunosorbent assay (ELISA) assays were performed to confirm the effects of BGM on the viability and inflammation of ox-LDL-induced HUVECs. Oil-red staining and immunoblot tests were conducted to determine the effects of BGM on foam cell formation and macrophage polarization. Furthermore, The mechanism of action of BGM was examined by immunoblot studies.
Results: BGM alleviated the ox-LDL-stimulated decline in HUVEC cell viability, and the ox-LDL-stimulated HUVEC inflammation, but inhibited ox-LDL-stimulated foam cell formation and macrophage polarization in vitro (p < 0.05). In addition, BGM regulated SIRT1/NF-κB pathway, thereby alleviating atherosclerosis (p < 0.05).
Conclusion: BGM regulates OX-LDL-induced inflammation and foam cell formation of HUVECs by mediating SIRT1/NF-κB pathway, and therefore can potentially serve as a drug for the treatment of atherosclerosis.
